Jeff has served as CEO of multiple life science companies in emerging healthcare markets with both public and private venture-backed companies. Prior to binx health, Jeff served as President, Chief Executive Officer, and Director of Good Start Genetics, a commercial stage provider of advanced genetic testing in reproductive health, with operations in all fifty states in the US. Under Jeff’s leadership, the company grew testing volumes by double digits, established transformative industry partnerships, and led the company’s successful sale to Invitae Corp. (NYSE: NVTA) in August 2017.
Prior to Good Start, Jeff co-founded SynapDx, Corp., a venture-backed developer of blood-based testing solutions for the early detection of autism. From 2002 to 2009 Jeff held numerous leadership roles with EXACT Sciences Corp., ultimately serving as its President, CEO, and Director where he led the company’s early commercial roll-out and won medical society endorsements for the company’s technologies, providing a strong platform for the company’s rapid growth and a transformative, high value partnership with Genzyme Corp. in 2009. Jeff has served on numerous boards of directors of both public and private companies and earned his Juris Doctor and MBA from Suffolk University.
Marc is a proven financial and operations executive who brings extensive expertise in leading financial, operational and business strategy aspects, and capital formation for both large and small, public and private healthcare and technology organizations. Prior to joining binx health, Marc was the COO & CFO of Good Start Genetics where he raised multiple successful rounds of capital, helped lead the impressive turnaround of the company to record business growth, and was instrumental in its ultimate sale to publicly traded Invitae.
Prior to Good Start Marc was CFO of T2 Biosystems, where he led the company’s preparation for and completion of an IPO and raised nearly $100M ($70M equity + $30M in debt); he built the finance team, implemented the necessary infrastructure and processes required of a public company, and he helped drive the commercialization of the company’s first FDA approved IVD product. Previously, Marc was CFO of Crashlytics where he oversaw the company’s acquisition by Twitter (the largest acquisition completed by Twitter at that time).
Before Crashlytics, Marc was CFO of Ivenix where he led all finance, admin, and operations functions, including raising over $8M in capital. Before that, Marc served as CFO of CHiL Semiconductor, where he oversaw growth from pre-revenue to a $20M run-rate, raised $30M in venture financing, and the ultimate acquisition of the company. Earlier in his career Marc held a number of other corporate finance positions ranging from Fortune 50 companies to high-growth startups.
As CTO, Anna plays a core leadership role at the binx health UK site, and is responsible for over-seeing and coordinating all technical product development activities. She leads in the expansion of the product menu, evolving the companys’ technology vision and strategy, as well as exploring novel applications of our core technology. Anna joined the company in 2007 and has extensive experience and expertise in molecular product development spanning early phase feasibility, reagent formulation and integration through to late phase development and verification. Under her leadership she has driven the company’s first product to enter US clinical trial for regulatory approval. Anna spent the early part of her career working in forensic science and in genetics research before obtaining a PhD in Human Genetics from the University of Oxford.
Board of directors
Stanley founded EXACT Sciences and served as its CEO and Chairman until 2006. Since commercial introduction of the company’s Cologuard test for non-invasive, early detection of colorectal cancer, EXACT has been the most rapidly growing company in the history of the diagnostics industry. Prior to EXACT Sciences, Stanley was founder and CEO of Cytyc Corp prior to its acquisition by Hologic for $6.2 billion. He is the principal inventor of Cytyc’s ThinPrep Pap test, which revolutionized screening for cervical cancer and now accounts for approximately 80% of the world market for cervical cancer screening. Stanley was also the founder and CEO of SynapDx and Helicos Biosciences. Currently, Stanley serves as a director to a number of public and private medical device and diagnostics companies, and he was an instructor at MIT from 2001 to 2017. Stanley is a seasoned innovator holding 36 U.S. patents. He was elected as a Fellow of the American Institute of Medical and Biological Engineering in 2013 for his work on the early detection of cancer. Stanley graduated from Cooper Union in New York City with a BS degree in electrical engineering.
Jeff has served as CEO of multiple life science companies in emerging healthcare markets with both public and private venture-backed companies. Prior to binx health, Jeff served as President, Chief Executive Officer, and Director of Good Start Genetics, a commercial stage provider of advanced genetic testing in reproductive health, with operations in all fifty states in the US. Under Jeff’s leadership, the company grew testing volumes by double digits, established transformative industry partnerships, and led the company’s successful sale to Invitae Corp. (NYSE: NVTA) in August 2017. Prior to Good Start, Jeff co-founded SynapDx, Corp., a venture-backed developer of blood-based testing solutions for the early detection of autism.
From 2002 to 2009 Jeff held numerous leadership roles with EXACT Sciences Corp., ultimately serving as its President, CEO, and Director where he led the company’s early commercial roll-out and won medical society endorsements for the company’s technologies, providing a strong platform for the company’s rapid growth and a transformative, high value partnership with Genzyme Corp. in 2009. Jeff has served on numerous boards of directors of both public and private companies and earned his Juris Doctor and MBA from Suffolk University.
Gail is a highly experienced healthcare executive with both domestic (U.S.) and international leadership assignments. She has worked in several healthcare sectors, including services, diagnostics, healthcare provision and managed care. She brings an in-depth understanding of the complex U.S. healthcare reimbursement environment and strong financial and operational leadership experience.
Gail has held leadership assignments in Fortune 100 healthcare companies, including United Healthcare and CIGNA, as well as small, private equity backed diagnostic organizations. She was named one of the top 100 women leaders in Massachusetts in 2014. Gail serves on the CMS advisory committee on diagnostic testing. She has an academic appointment at Massachusetts College of Pharmacy and Health Sciences (MCPHS University), leading a cross section of programs in pharmaceutical business and administrative sciences. Gail holds a B.A. from Wesleyan University, a M.B.A in Accounting and Decision Sciences from the Wharton School, a M.S.E in computer science from the University of Pennsylvania and a doctorate in healthcare administration from the Medical University of South Carolina. She currently serves on two public company boards, Natera (NTRA) and Triple S (TSM) and achieved the Leadership Fellow designation from the National Association of Corporate Directors. Ms. Marcus meets the requirements of a financial expert.
Dr. Moonly is a former investment banker at Merrill Lynch where he was an analyst on the largest Biotech Merger at that time – Amgen’s purchase of Immunex. Additionally, he completed a follow on offering for biotech, and analyzed multiple M&A deals in the medical technology space.
Scott was also a strategy consultant with L.E.K. Consulting where he developed the Oncology strategy for a large Biotech company. Additionally, he helped to develop the healthcare royalty securitization industry as lead consultant on multiple landmark deals in the space. Additionally, he provided guidance on the largest generic drug merger at the time.
Dr. Moonly also has experience as a Venture Capitalist with Johnson & Johnson Development Corporation (JJDC), the Venture Capital arm of Johnson and Johnson. While there he completed many investments in the medical technology, digital health and Venture Capital fund space. He led the relationships with Ethicon Endosurgery, and Cordis, helping each organization develop their investing and corporate strategies. Additionally, developed white space investing strategies for the Venture Capital group, most notably their digital health strategy.
President and CEO of USGI Medical. Increased sales ~300% over 3 years, developed finalized procedure for weight loss, and led the execution of multiple landmark studies including a U.S. pivotal trial. During this time period, Scott raised ~$50M in equity and debt for the company including a large investment by Johnson and Johnson to fund the US pivotal trial.
Dr. Moonly holds a Bachelors of Science in Bioengineering from University of California (San Diego, 1993-1998) and a PhD in Bioengineering from University of California, Berkeley/ University of California, San Francisco (1998-2003).
Dr. Münchbach has been a Managing Partner and Investment Advisor Private Equity at BB Biotech Ventures and Bellevue Asset Management since 2004. He has been an active venture capitalist since the late 90’s investing in life science companies across all stages and types. Prior to joining Bellevue Group, he was Investment Manager at BioMed, HBM, and NMT. Dr. Münchbach’s past and current board assignments include Bellevue’s most successful private biopharmaceutical investments, such as Radius Health, Molecular Partners, Optimer Pharmaceuticals, Axovan, and Glycart. Dr. Münchbach holds a PhD in Protein Chemistry, an MSc in Biochemistry, and a Masters in Industrial Engineering and Management from the Swiss Federal Institute of Technology (ETH), Zürich.
Joachim (JR) Rothe, PhD, joined LSP in 2002 and is a Managing Partner of the firm. Prior to joining LSP, Joachim was the Managing Director of MPM Capital Germany, a US healthcare investment firm, where he rose to head up their European investment franchise. Previously, he worked at McKinsey & Company in Germany and at Roche in Switzerland. He serves or has served on the boards of 4-Antibody (CH, now NASDAQ: AGEN), Affectis (D), binx health (UK), Atugen (D, now LSE:SLN Silence Therapeutics), Bioxell (I, now SIX: Cosmo Pharmaceuticals), Cardior (D), Cellerix (E, now NYSE Euronext: Tigenix), IDEA (D), Morphochem (D, now: Biovertis), Idenix (USA, then NASDAQ: IDIX, now Merck), Luxendo (D, now Bruker Corp), Nouscom (CH), Okairos (CH, now: GSK), Omrix Biopharmaceuticals (NYSE: OMRI, then J&J), Scion Pharmaceuticals (USA), t.Breeders (NASDAQ: Viacell, then NYSE:PKI), and U3 Pharma (D, now: Daiichi-Sankyo).
In addition, he serves pro bono on the boards of various tech transfer organizations such as Ascenion, AWS, or the Life Science Incubator. Joachim obtained a master’s degree in Biochemistry from the Free University in Berlin and a PhD in Molecular Immunology from Freiburg University. His thesis was supervised by Georges Köhler, a Nobel laureate in Medicine. Joachim has authored numerous articles in leading scientific publications, including Nature.
Carl-Johan is SVP Strategic Investments and Projects at Recipharm, a leading CDMO company, and based in Sweden heading the subsidiary Recipharm Venture Fund AB. He has previously served as EVP Development Services in Recipharm for many years. Carl-Johan has more than 30 years’ experience from the pharmaceutical industry with positions as managing director and CEO in small start-up companies as well as larger pharmaceutical companies. He presently serves on several biotech boards, public as well as private companies and both pharma and medtech, like Prokarium Ltd, KAHR Medical Ltd, Atrogi AB, Symcel Sweden AB, Follicum AB, Empros Pharma AB, Pharmacolog AB, Synthonics Inc, Inject Pharma AB and Xspray Pharma AB. Carl-Johan is a director in the Swedish trade association SwedenBIO. Carl-Johan has a PhD in dentistry and pharmacology at Karolinska Institutet in Stockholm, Sweden.
Jihua has served on the board of directors of since January 2017. As a member of the first generation of pioneers in establishing private biotechnology companies in China, Jihua founded Guangzhou Wondfo Biotech Co., Ltd, in 1992, and served as the CEO until June 2016. After leading the company to IPO in 2015, Jihua has been appointed Chairman of the Board since July 2016. Since 2009, Jihua has been the President of Wondfo USA, where she oversees global strategic planning. She has extensive experience in IVD technology and healthcare business. Jihua received a B.S. from Hunan Medical University and M.S. from State Key Laboratory of Enzyme Engineering of Jilin University. She worked as a visiting scholar at Harvard Medical School in 2000.